The prescriptive paradox of allergen immunotherapy for respiratory allergic diseases

Allergy immunotherapy (AIT) is an effective, safe, and cost-efficient treatment for allergic rhinitis and asthma. Nevertheless, the prescription of AIT is paradoxically low and is progressively decreasing in Italy. Barriers exist, including the lack of guidelines for primary care physicians (PCPs) and specialists, insufficient agreed-upon pathways between specialists and PCPs, and complexities in the prescriptive process. It is necessary to rethink the approach to this issue through a collaborative and integrated effort among all players involved in improving accessibility and utilization of AIT for the treatment of allergic respiratory diseases